News today - Detailed Results - Webinar later today. Here are the first couple of paragraphs of the News Release issued today:
2021-05-20 07:28 ET - News Release
- Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment
- Dr. Ilse Roodink and Dr. Debby Kruijsen to host live webinar “Function First: Using complementary antibody platforms to fight Covid-19” today at 11:00 am Eastern Daylight Time
Company Website: https://www.immunoprecise.com
VICTORIA, British Columbia -- (Business Wire)
ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ: IPA) (TSX venture: IPA) announces the completion of an efficacy-driven, preclinical study demonstrating further evidence of the in vivo efficacy of a four monoclonal antibody cocktail against non-overlapping epitopes, utilizing an optimized formulation and, for the first time, demonstrating therapeutic synergy of the cocktail components in vivo.
Highlights of the study include:
- Completed preclinical efficacy studies for its newly optimized 4-antibody cocktail (TATX-03b), showing strong in vivo therapeutic efficacy and synergy for the treatment and protection against SARS-CoV-2 infection
- The Company believes these are the first publicly reported in vivo synergistic effects of a multi-antibody (3+) combination treatment
- IPA’s optimized, 4-Ab cocktail (TATX-03b) shows high levels of efficacy in treating SARS-CoV-2 in the preclinical study
- Updated mutant binding data demonstrates continued in vitro resistance against novel variants of concern, including the recently described Californian and New York variants
- Company contracts ChemPartner Biologics (Shanghai) Co., Ltd. for optimized, stable CHO pool generation and cell bank generation for use in cGMP manufacturing
Live Webinar Today – ““Function First: Using complementary antibody platforms to fight Covid-19” will be aired at 11:00 am Eastern Daylight Time (New York, GMT-04:00).
To learn how IPA's PolyTope™ approach is designed to prevent the spread of novel variants, treat COVID-19, and prevent infection by SARS-CoV-2 and its variants, register for ImmunoPrecise’s webinar, to be held today, Thursday, May 20, 2021, hosted by Dr. Ilse Roodink and Dr. Debby Kruijsen.